Press releases

Boston Scientific will participate in the healthcare conference on May 15 in Las Vegas. Learn how to watch the webcast or replay.

New line of ablation catheters for treating type 1 atrial flutter is designed to provide physicians with high resolution, precise, multidimensional information.

Forty-two clinical presentations will provide new insights about Boston Scientific research in cardiovascular disease, including atrial fibrillation and sudden cardiac arrest.

"We continue to be encouraged but not satisfied with our operating performance," said CEO Mike Mahoney.

Earth Week celebration focuses on 3,900-panel project at the company’s international distribution center in Quincy.

Innovative device quickly anchors leads and catheters.

SAMURAI study designed to confirm the safety and effectiveness of ImageReady™ MR Conditional pacing system in the magnetic resonance imaging (MRI) environment.

World's first and only system with Illumina 3D™ software and 32 contacts is designed to provide pain relief to a broad spectrum of chronic pain patients.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2013. Learn how to tune in.

Results Revealed at CIT 2013

Deadly but preventable cancer is a focus during colorectal cancer awareness month

Separate study demonstrates PROMUS Element stent has significantly less vessel straightening than the Xience V® stent.

WATCHMAN® device continues to demonstrate positive clinical outcomes for patients with atrial fibrillation.

Preliminary data in PREVAIL clinical trial met two out of three co-primary endpoints.

First presentation of the preliminary results of all three co-primary endpoints to be revealed during American College of Cardiology 2013 Annual Scientific Sessions.

New tool available to assist in the treatment of peripheral arterial disease.

Clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.

Boston Scientific will participate in the healthcare conference on February 26 in New York. Learn how to watch the webcast or replay.

Extensive sales resources, distribution network and service capabilities are expected to enable Boston Scientific to reach substantially more accounts, customers and patients in Japan.

Boston Scientific will participate in the healthcare conference on February 25 in New York. Learn how to watch the webcast or replay.

The next advance in durable polymer stent technology from Boston Scientific is now available in Europe and other select geographies.

Boston Scientific will participate in the healthcare conference on February 13 in New York. Learn how to watch the webcast or replay.

Organizations team up to raise awareness and make a call to action for European governments to develop comprehensive chronic pain treatment programs.

“I am confident we are taking the critical steps that are needed to return our company to long-term growth,” said president and CEO Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and FY ended December 31. Learn how to tune in.

International, multi-center study focuses on patients with paroxysmal atrial fibrillation.

Learn how to tune in or watch the Investor Day replay.

A live webcast and replay will be available. Learn how to tune in.

Company begins evaluation of its next generation pacing leads.

Close the Gap initiative urges fans to learn their risk factors for heart disease.

World's first and only system with 32 contacts and 32 dedicated power sources is designed to provide pain relief to a broad spectrum of chronic pain patients.

Study to compare clinical outcomes of self-expanding metal stents (SEMS) versus plastic stents for the treatment of biliary strictures caused by chronic pancreatitis.

Stent system study to support FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions; received CE approval last month.

Devices projected to have up to twice the longevity of comparable products.

Company to consolidate Natick, Mass. headquarters into existing Marlborough site to create collaborative campus setting; to be completed by summer 2014.

MADIT-RIT clinical trial study results published today in the New England Journal of Medicine

Appointment completes company's CEO transition plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman.

Innovative bioabsorbable coating is the first to complete absorption shortly after drug elution ends at three months.

Language update supports the strong safety profile for PROMUS Element and PROMUS Element Plus Stents.

PLATINUM Long Lesion clinical results presented at TCT 2012 show no heart attack or stent thrombosis at two-year follow-up.

Twelve-month data presented at TCT 2012 support safety and efficacy of Epic stent in iliac stenting.

Results presented on cost effectiveness and clinical benefits for older patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System feasibility trial results reviewed.

Clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and atrial fibrillation.

"We remain focused on executing our strategy to drive this organization back to revenue growth,” said CEO Hank Kucheman.

REPRISE II study results expected to support CE Mark and other regulatory filings.

Victory™ guidewires are designed to facilitate crossing of resistant lesions.

Pending addition of next generation mapping and navigation system would expand company portfolio into complex electrophysiology procedures.

Learn how to tune in for the webcast or the replay.

Disorders affect nearly 30 million American women; new research shows high prevalence of patients not understanding their treatment options.

S-ICD System is the world's first and only commercially available completely subcutaneous implantable defibrillator.

S-ICD System is world's first and only commercially available completely subcutaneous implantable defibrillator.

First and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions

RELIANCE® 4-FRONT™ lead designed to streamline surgical procedure for treatment of heart failure and sudden cardiac arrest.

Company to acquire innovative, minimally invasive technologies for the treatment of coronary chronic total occlusions.

New bronchial thermoplasty procedure codes effective January 1, 2013.

Boston Scientific will participate in the healthcare conference on September 12. Learn how to watch the webcast or replay.

System is the world's first rechargeable SCS device; approval provides physicians with an additional diagnostic option for patients with chronic intractable pain.

World's first rechargeable SCS device approved for peripheral nerve stimulation for patients with chronic intractable pain of the trunk.

Newly revised European Society of Cardiology guidelines include LAA closure devices.

PARIS (July 27, 2012) -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June...

Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...

Boston Scientific Corporation (NYSE: BSX) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26, at 8:00 a.m....

Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...

Boston Scientific Corporation (NYSE: BSX) welcomes final passage today by the United States Senate of "The Food and Drug Administration Safety and...

Natick, MA (June 14, 2012) –Warren Wang has been appointed Vice President and Managing Director of Boston Scientific Corporation’s (NYSE:BSX) operations in China. Mr. Wang is responsible for...

Next-generation wireless remote patient management system enabled for INGENIO™ family of pacemakers is now in use in Europe

Adds first and only commercially available subcutaneous ICD technology that offers new life-saving therapy option to patients at risk of sudden cardiac arrest.

Medical device tax would stifle innovation

Event to be webcast live and will include detailed review of Bronchial Thermoplasty opportunity.

PROMUS Element plus stent system offers physicians the broadest array of Everolimus drug-eluting stent lengths and diameters in the U.S.

Devices projected to have nearly twice the longevity of comparable products

Indication provides new therapeutic option for extraction of difficult-to-manage biliary stones

Seven abstracts and data analyses to be presented May 19 – 22 in San Diego.

Two-year clinical data demonstrate low adverse event rates, including no myocardial infarction or stent thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent

New self-expanding Nitinol stent offers balance of flexibility and radial strength for enhanced performance in iliac stenting procedures.

Follow-up data from EVOLVE Trial presented at EuroPCR.

Results of REPRISE I study suggest device minimizes aortic regurgitation

Innovative stent designed to treat peripheral vascular lesions for stenoses in arteries above the knee.

Collaboration expected to improve access to imaging data used to treat patients.

Results presented at Heart Rhythm Society from ASA Plavix study evaluating Boston Scientific Left Atrial Appendage Closure Device.

Clinical presentations to include 12-month outcomes data from EVOLVE trial and results of the REPRISE I trial.

Advanced pacemaker platform designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

Clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

A live webcast and replay of the May 8 session will be available. Read more.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions.

REPRISE I Trial Results to be Presented at EuroPCR 2012

Fesults “demonstrate continued progress towards improving our future growth profile and in executing our strategic plan," said CEO Hank Kucheman.

Device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 2012 on April 19. Learn how to tune in or watch the replay.

Advanced devices designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

BackStop Gel is a water-soluble polymer that urologists inject into the ureter to form a plug behind the stone, preventing migration of stone fragments of all sizes.

CTAF report supports safety, efficacy and positive health outcomes of bronchial thermoplasty for treatment of patients with severe asthma.

HORIZONS II AMI trial to enroll up to 10,000 patients worldwide, making it the largest randomized trial to study coronary stents in heart attack patients.

Results were presented at the American College of Cardiology Annual Scientific Sessions.

Quantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012.

Company's WallFlex Biliary Stents now available with a Transhepatic delivery system for use by interventional radiologists in treating obstructions within the biliary tract.

Data to include two-year results from the PLATINUM Workhorse clinical trial, with follow-up data on PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent.

Priority Health and HealthPartners issue new medical policies to cover catheter-based procedure shown to provide long-lasting control of severe asthma.